Denali Therapeutics Inc (NASDAQ:DNLI) COO Alexander O. Schuth Sells 7,500 Shares

Denali Therapeutics Inc (NASDAQ:DNLI) COO Alexander O. Schuth sold 7,500 shares of Denali Therapeutics stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $18.77, for a total value of $140,775.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

DNLI opened at $18.71 on Friday. The stock has a market capitalization of $1.79 billion, a P/E ratio of -47.97 and a beta of 2.28. Denali Therapeutics Inc has a 12 month low of $12.32 and a 12 month high of $28.86. The company has a quick ratio of 11.55, a current ratio of 11.55 and a debt-to-equity ratio of 0.14.

Denali Therapeutics (NASDAQ:DNLI) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($0.41) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.40) by ($0.01). The company had revenue of $4.21 million during the quarter, compared to analysts’ expectations of $12.88 million. Denali Therapeutics had a negative return on equity of 10.23% and a negative net margin of 38.84%. Analysts anticipate that Denali Therapeutics Inc will post -1.48 earnings per share for the current year.

DNLI has been the subject of several recent research reports. TheStreet lowered Denali Therapeutics from a “c-” rating to a “d” rating in a research report on Thursday. ValuEngine lowered Denali Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, May 28th. Finally, Zacks Investment Research lowered Denali Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, May 2nd. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. Denali Therapeutics presently has a consensus rating of “Buy” and a consensus price target of $26.00.

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. TD Asset Management Inc. grew its position in Denali Therapeutics by 2.2% in the first quarter. TD Asset Management Inc. now owns 23,400 shares of the company’s stock worth $543,000 after acquiring an additional 500 shares in the last quarter. Principal Financial Group Inc. grew its position in Denali Therapeutics by 0.4% in the first quarter. Principal Financial Group Inc. now owns 186,760 shares of the company’s stock worth $4,337,000 after acquiring an additional 810 shares in the last quarter. BlueMountain Capital Management LLC purchased a new position in Denali Therapeutics in the first quarter worth about $26,000. Legal & General Group Plc grew its position in Denali Therapeutics by 16.3% in the fourth quarter. Legal & General Group Plc now owns 8,638 shares of the company’s stock worth $179,000 after acquiring an additional 1,212 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank grew its position in Denali Therapeutics by 13.4% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 10,436 shares of the company’s stock worth $216,000 after acquiring an additional 1,237 shares in the last quarter. Institutional investors own 71.69% of the company’s stock.

COPYRIGHT VIOLATION WARNING: “Denali Therapeutics Inc (NASDAQ:DNLI) COO Alexander O. Schuth Sells 7,500 Shares” was first published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this report on another website, it was stolen and reposted in violation of U.S. and international copyright law. The legal version of this report can be accessed at https://www.dispatchtribunal.com/2019/06/15/denali-therapeutics-inc-nasdaqdnli-coo-alexander-o-schuth-sells-7500-shares.html.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 and DNL151, which are in Phase 1 clinical trials for Parkinson's disease.

See Also: Do investors pay a separate front-end load every time they buy additional shares?

Insider Buying and Selling by Quarter for Denali Therapeutics (NASDAQ:DNLI)

Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.